Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| P21 (Cerebrolysin Analog) | Tesamorelin | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 750 mcg-1 mg daily via intranasal administration or subcutaneous injection. | Research indicates 2 mg administered once daily via subcutaneous injection (FDA-approved dose for HIV lipodystrophy). |
| Timing | Morning dosing preferred for cognitive effects. | Morning administration on empty stomach. Consistent daily timing recommended. |
| Cycle Duration | 4-8 week cycles with 4-week rest periods. | 26+ weeks in clinical trials. Long-term use is common; effects are not sustained after discontinuation. |
| Evidence Level | animal_plus_anecdotal | Strong (FDA-approved indication), Moderate (longevity) |
P21 is a tetrapeptide (DGGL — Asp-Gly-Gly-Leu) derived from the most active region of ciliary neurotrophic factor (CNTF, residues 148-151), identified through reverse engineering of Cerebrolysin. An adamantylated glycine enhances BBB permeability and metabolic stability. P21 works through LIF/STAT3 pathway inhibition, BDNF/TrkB/CREB signaling enhancement, and restoration of synaptic proteins (synaptophysin, synapsin I) and glutamate receptors. It promotes neurogenesis and maturation of newborn neurons in the dentate gyrus.
Research indicates 750 mcg-1 mg daily via intranasal administration or subcutaneous injection.
Morning dosing preferred for cognitive effects.
4-8 week cycles with 4-week rest periods.
Tesamorelin is an FDA-approved synthetic 44-amino acid GHRH analog with a trans-3-hexenoic acid modification at the N-terminal tyrosine that confers resistance to DPP-IV degradation. It binds GHRH receptors on anterior pituitary somatotrophs, stimulating endogenous GH production and secretion while maintaining pulsatile release patterns. Tesamorelin selectively reduces visceral adipose tissue (15-20% reduction in trials) while preserving subcutaneous fat, and markedly increases plasma GH and IGF-1 levels with once-daily dosing.
Research indicates 2 mg administered once daily via subcutaneous injection (FDA-approved dose for HIV lipodystrophy).
Morning administration on empty stomach. Consistent daily timing recommended.
26+ weeks in clinical trials. Long-term use is common; effects are not sustained after discontinuation.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →